Karen Nelson - Thermo Fisher Chief Officer
| TMO Stock | USD 513.26 2.84 0.55% |
Executive
Karen Nelson is Chief Officer of Thermo Fisher Scientific
| Address | 168 Third Avenue, Waltham, MA, United States, 02451 |
| Phone | 781 622 1000 |
| Web | https://www.thermofisher.com |
Thermo Fisher Management Efficiency
The company has Return on Asset of 0.0467 % which means that on every $100 spent on assets, it made $0.0467 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1294 %, implying that it generated $0.1294 on every 100 dollars invested. Thermo Fisher's management efficiency ratios could be used to measure how well Thermo Fisher manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to 0.09. In addition to that, Return On Capital Employed is likely to drop to 0.05. At this time, Thermo Fisher's Other Assets are very stable compared to the past year. As of the 25th of November 2024, Fixed Asset Turnover is likely to grow to 4.79, while Net Tangible Assets are likely to drop (13.7 B).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Claudia Levi | DarioHealth Corp | N/A | |
| LLM JD | MDxHealth SA ADR | 59 | |
| Mona Dean | DarioHealth Corp | N/A | |
| Tomer BenKiki | DarioHealth Corp | 53 | |
| Joseph Vitale | Sotera Health Co | N/A | |
| MBA MS | Exagen Inc | 45 | |
| John Wegener | Exagen Inc | 55 | |
| Danielle Menture | Sotera Health Co | N/A | |
| Kathleen Hoffman | Sotera Health Co | N/A | |
| Jeffrey Black | Exagen Inc | 55 | |
| Dror Bacher | DarioHealth Corp | 49 | |
| Benjamin JD | Sera Prognostics | 45 | |
| Joseph Sollee | MDxHealth SA ADR | 59 | |
| Hao Liu | Burning Rock Biotech | 50 | |
| Limor Drezner | DarioHealth Corp | N/A | |
| Austin Aerts | Sera Prognostics | 37 | |
| Ron CPA | MDxHealth SA ADR | 50 | |
| Omar MD | DarioHealth Corp | N/A | |
| Miriam Reyes | MDxHealth SA ADR | 51 | |
| Lisa MetznerRosas | Neuronetics | N/A | |
| Jason Poole | MDxHealth SA ADR | N/A | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0467 |
Thermo Fisher Scientific Leadership Team
Elected by the shareholders, the Thermo Fisher's board of directors comprises two types of representatives: Thermo Fisher inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Thermo. The board's role is to monitor Thermo Fisher's management team and ensure that shareholders' interests are well served. Thermo Fisher's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Thermo Fisher's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jim Manzi, Independent Chairman of the Board | ||
| Michel Lagarde, Senior Vice President and President, Pharma Services | ||
| Mark Stevenson, Executive VP and President of Life Sciences Solutions | ||
| Rafael Tejada, Vice Relations | ||
| Stephen Williamson, Chief Financial Officer, Senior Vice President | ||
| Tyler Jacks, Independent Director | ||
| James Mullen, Independent Director | ||
| Dion Weisler, Independent Director | ||
| Karen Nelson, Chief Officer | ||
| Debora Spar, Independent Director | ||
| Peter Hornstra, Vice President Chief Accounting Officer | ||
| Judy Lewent, Independent Director | ||
| Michael Boxer, Senior Vice President General Counsel | ||
| Ruby Chandy, Director | ||
| Joseph Holmes, Chief Accounting Officer, Vice President | ||
| Lars Sorensen, Independent Director | ||
| C Harris, Independent Director | ||
| Elaine Ullian, Independent Director | ||
| Thomas Lynch, Director, Chairman of Nominating and Corporate Governance Committee and Member of Compensation Committee | ||
| Ryan Snyder, Senior Officer | ||
| Nelson Chai, Independent Director | ||
| Lisa Britt, Chief VP | ||
| Syed Jafry, Senior Vice President and President Regions | ||
| Marc Casper, CEO and President Director, Member of Strategy and Fin. Committee and Member of Science and Technology Committee | ||
| Michael Esq, Senior Counsel | ||
| Sandy Pound, VP Officer | ||
| Scott Sperling, Independent Director | ||
| R Keith, Independent Director | ||
| Gianluca Pettiti, Senior Vice President and Presidentident - Specialty Diagnostics business |
Thermo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Thermo Fisher a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0467 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 224.99 B | ||||
| Shares Outstanding | 382.5 M | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 90.92 % | ||||
| Number Of Shares Shorted | 2.93 M | ||||
| Price To Earning | 30.99 X |
Pair Trading with Thermo Fisher
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Thermo Fisher position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Thermo Fisher will appreciate offsetting losses from the drop in the long position's value.Moving together with Thermo Stock
| 0.77 | A | Agilent Technologies Earnings Call Today | PairCorr |
| 0.91 | ME | 23Andme Holding | PairCorr |
| 0.73 | VALN | Valneva SE ADR | PairCorr |
Moving against Thermo Stock
| 0.87 | EXEL | Exelixis | PairCorr |
| 0.85 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.65 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.47 | KTTAW | Pasithea Therapeutics | PairCorr |
The ability to find closely correlated positions to Thermo Fisher could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Thermo Fisher when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Thermo Fisher - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Thermo Fisher Scientific to buy it.
The correlation of Thermo Fisher is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Thermo Fisher moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Thermo Fisher Scientific moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Thermo Fisher can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Thermo Fisher Scientific. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Thermo Fisher. If investors know Thermo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Thermo Fisher listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.04) | Dividend Share 1.52 | Earnings Share 15.96 | Revenue Per Share 110.627 | Quarterly Revenue Growth 0.002 |
The market value of Thermo Fisher Scientific is measured differently than its book value, which is the value of Thermo that is recorded on the company's balance sheet. Investors also form their own opinion of Thermo Fisher's value that differs from its market value or its book value, called intrinsic value, which is Thermo Fisher's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Thermo Fisher's market value can be influenced by many factors that don't directly affect Thermo Fisher's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Thermo Fisher's value and its price as these two are different measures arrived at by different means. Investors typically determine if Thermo Fisher is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Thermo Fisher's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.